Mike Davitt

could you also update us on how you see the gross-to-net tracking in the second half after a positive surprise there in 2Q

Do you have any early thoughts on how much exposure your portfolios could have to that? And does that cut in funding change your view on the Life Sciences investment opportunity

can you remind on the cadence each year on when those lumpier plan losses can occur